THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 118 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is 7.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,147 | -81.1% | 5,579 | -77.4% | 0.00% | – |
| Q2 2023 | $254,952 | +233.4% | 24,633 | +249.5% | 0.00% | – |
| Q1 2023 | $76,471 | -15.0% | 7,048 | -12.1% | 0.00% | – |
| Q4 2022 | $89,973 | -23.8% | 8,019 | -31.3% | 0.00% | – |
| Q3 2022 | $118,000 | -27.2% | 11,666 | -34.8% | 0.00% | – |
| Q2 2022 | $162,000 | -17.8% | 17,900 | -13.1% | 0.00% | – |
| Q1 2022 | $197,000 | -12.8% | 20,592 | +0.6% | 0.00% | – |
| Q4 2021 | $226,000 | -16.6% | 20,473 | -44.0% | 0.00% | – |
| Q3 2021 | $271,000 | +88.2% | 36,590 | +269.4% | 0.00% | – |
| Q2 2021 | $144,000 | +12.5% | 9,905 | +57.7% | 0.00% | – |
| Q1 2021 | $128,000 | -65.5% | 6,279 | -69.9% | 0.00% | – |
| Q4 2020 | $371,000 | +159.4% | 20,868 | +115.7% | 0.00% | – |
| Q3 2020 | $143,000 | -82.5% | 9,673 | -75.2% | 0.00% | -100.0% |
| Q2 2020 | $819,000 | +89.6% | 38,975 | +108.7% | 0.00% | – |
| Q1 2020 | $432,000 | +21.3% | 18,675 | +36.1% | 0.00% | – |
| Q4 2019 | $356,000 | +158.0% | 13,724 | +92.5% | 0.00% | – |
| Q3 2019 | $138,000 | -40.3% | 7,129 | -49.7% | 0.00% | – |
| Q2 2019 | $231,000 | -18.9% | 14,180 | +12.5% | 0.00% | – |
| Q1 2019 | $285,000 | +71.7% | 12,604 | +94.5% | 0.00% | – |
| Q4 2018 | $166,000 | +181.4% | 6,481 | +258.5% | 0.00% | – |
| Q3 2018 | $59,000 | +555.6% | 1,808 | +380.9% | 0.00% | – |
| Q2 2018 | $9,000 | +80.0% | 376 | +72.5% | 0.00% | – |
| Q1 2018 | $5,000 | -50.0% | 218 | -39.1% | 0.00% | – |
| Q4 2017 | $10,000 | -97.0% | 358 | -96.3% | 0.00% | – |
| Q3 2017 | $332,000 | +4050.0% | 9,692 | +5001.1% | 0.00% | – |
| Q2 2017 | $8,000 | -99.7% | 190 | -99.7% | 0.00% | -100.0% |
| Q1 2017 | $2,411,000 | +306.6% | 65,491 | +252.4% | 0.00% | +100.0% |
| Q4 2016 | $593,000 | +178.4% | 18,585 | +215.4% | 0.00% | – |
| Q3 2016 | $213,000 | +36.5% | 5,893 | -14.3% | 0.00% | – |
| Q2 2016 | $156,000 | -59.4% | 6,875 | -66.4% | 0.00% | – |
| Q1 2016 | $384,000 | +115.7% | 20,442 | +88.2% | 0.00% | – |
| Q4 2015 | $178,000 | – | 10,861 | +271425.0% | 0.00% | – |
| Q3 2015 | $0 | -100.0% | 4 | -99.9% | 0.00% | – |
| Q2 2015 | $70,000 | -41.7% | 5,405 | -21.3% | 0.00% | – |
| Q1 2015 | $120,000 | -41.7% | 6,867 | -50.2% | 0.00% | – |
| Q4 2014 | $206,000 | +390.5% | 13,800 | +656.2% | 0.00% | – |
| Q3 2014 | $42,000 | -16.0% | 1,825 | +16.2% | 0.00% | – |
| Q2 2014 | $50,000 | – | 1,570 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |